BCR and chronic myelogenous leukemia, BCR-ABL1 positive: For example, mutations in the BCR-ABL kinase domain have been shown to confer resistance to Imatinib in chronic myeloid leukemia (CML) by disrupting inhibitor binding and reducing therapeutic efficacy [59].